Markov model schematic of the 3 assay TATs (rapid, in-house, and send-out). All patients (PLASMIC = 5 or PLASMIC = 6-7) undergo treatment with TPE with or without caplacizumab. Unlike the rapid strategy, this treatment is empiric with in-house and send-out testing until 24 and 72 hours, respectively, after which only treatment for patients with confirmed iTTP is continued. Capla, caplacizumab.